Immunological Changes After COVID-19 Vaccination in an HIV-positive Patient

Overview

Journal Int J Infect Dis

Publisher Elsevier

Specialty Infectious Diseases

Date 2021 Aug 22

PMID 34419582

Citations 6

Authors

Changlin Gong

Xiaojing Song

Xiaoxia Li

Lianfeng Lu

Taisheng Li

Affiliations

Soon will be listed here.

Abstract

Vaccination is an essential measure to stop the coronavirus disease 2019 (COVID-19) pandemic. We report a case of viral activation and CD4+ T cell loss in a treatment-naïve HIV-positive patient after receiving inactivated COVID-19 vaccine (Sinopharm). The vaccine should probably be given only to people living with HIV receiving antiretroviral therapy.

Citing Articles

Efficacy, safety, and public attitude toward COVID-19 vaccines: A systematic review.

Josiah B, Uzor C, Duncan B, Enebeli E, Otoboyor N Ann Afr Med. 2024; 22(4):405-414.

PMID: 38358138 PMC: 10775944. DOI: 10.4103/aam.aam_13_23.

Effect of SARS-CoV-2 Breakthrough Infection on HIV Reservoirs and T-Cell Immune Recovery in 3-Dose Vaccinated People Living with HIV.

Qu M, Song B, Yang B, Wang Z, Yu M, Zhang Y Viruses. 2023; 15(12).

PMID: 38140668 PMC: 10748120. DOI: 10.3390/v15122427.

Progressive Worsening of Neurological Manifestations in HIV-Associated Opportunistic Central Nervous System (CNS) Infection Patients After COVID-19 Vaccinations: A Possible Co-Incidence Causality.

Hanif F, Satiti S, Subagya S, Retnowulan H, Subronto Y, Mulya D Am J Case Rep. 2022; 23:e936257.

PMID: 35610955 PMC: 9150601. DOI: 10.12659/AJCR.936257.

Safety and immunogenicity of inactivated SARS-CoV-2 vaccines in people living with HIV.

Ao L, Lu T, Cao Y, Chen Z, Wang Y, Li Z Emerg Microbes Infect. 2022; 11(1):1126-1134.

PMID: 35369854 PMC: 9037169. DOI: 10.1080/22221751.2022.2059401.

Factors Associated with Intention to Receive COVID-19 Vaccine Among HIV Positive Patients Attending ART Clinic in Southwest Ethiopia.

Mesfin Y, Argaw M, Geze S, Zewdu B Patient Prefer Adherence. 2021; 15:2731-2738.

PMID: 34916783 PMC: 8668249. DOI: 10.2147/PPA.S342801.

References

Stanley S, Ostrowski M, Justement J, Gantt K, Hedayati S, Mannix M . Effect of immunization with a common recall antigen on viral expression in patients infected with human immunodeficiency virus type 1. N Engl J Med. 1996; 334(19):1222-30. DOI: 10.1056/NEJM199605093341903. View

Yang S, Li Y, Dai L, Wang J, He P, Li C . Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials. Lancet Infect Dis. 2021; 21(8):1107-1119. PMC: 7990482. DOI: 10.1016/S1473-3099(21)00127-4. View

Katzenstein T . Pneumococcal vaccination of HIV-infected individuals: safety and efficacy. AIDS Patient Care STDS. 1997; 11(4):269-75. DOI: 10.1089/apc.1997.11.269. View

Tesoriero J, Swain C, Pierce J, Zamboni L, Wu M, Holtgrave D . COVID-19 Outcomes Among Persons Living With or Without Diagnosed HIV Infection in New York State. JAMA Netw Open. 2021; 4(2):e2037069. PMC: 7859843. DOI: 10.1001/jamanetworkopen.2020.37069. View

Al Kaabi N, Zhang Y, Xia S, Yang Y, Al Qahtani M, Abdulrazzaq N . Effect of 2 Inactivated SARS-CoV-2 Vaccines on Symptomatic COVID-19 Infection in Adults: A Randomized Clinical Trial. JAMA. 2021; 326(1):35-45. PMC: 8156175. DOI: 10.1001/jama.2021.8565. View

Haynes B . SARS-CoV-2 and HIV-1 - a tale of two vaccines. Nat Rev Immunol. 2021; 21(9):543-544. PMC: 8284417. DOI: 10.1038/s41577-021-00589-w. View

Eisinger R, Lerner A, Fauci A . Human Immunodeficiency Virus/AIDS in the Era of Coronavirus Disease 2019: A Juxtaposition of 2 Pandemics. J Infect Dis. 2021; 224(9):1455-1461. PMC: 8083774. DOI: 10.1093/infdis/jiab114. View

Tanriover M, Doganay H, Akova M, Guner H, Azap A, Akhan S . Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021; 398(10296):213-222. PMC: 8266301. DOI: 10.1016/S0140-6736(21)01429-X. View

Baden L, El Sahly H, Essink B, Kotloff K, Frey S, Novak R . Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine. N Engl J Med. 2020; 384(5):403-416. PMC: 7787219. DOI: 10.1056/NEJMoa2035389. View

10.

. [Expert recommendation for novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination in patients with HIV infection]. Zhonghua Nei Ke Za Zhi. 2021; 60(7):615-618. DOI: 10.3760/cma.j.cn112138.20210403-00259. View

11.

Berkowitz E, Moyle G, Stellbrink H, Schurmann D, Kegg S, Stoll M . Safety and immunogenicity of an adjuvanted herpes zoster subunit candidate vaccine in HIV-infected adults: a phase 1/2a randomized, placebo-controlled study. J Infect Dis. 2014; 211(8):1279-87. PMC: 4371767. DOI: 10.1093/infdis/jiu606. View

12.

Peng X, Ouyang J, Isnard S, Lin J, Fombuena B, Zhu B . Sharing CD4+ T Cell Loss: When COVID-19 and HIV Collide on Immune System. Front Immunol. 2021; 11:596631. PMC: 7770166. DOI: 10.3389/fimmu.2020.596631. View

13.

Rousseau M, Moreau J, Delmont J . Vaccination and HIV: a review of the literature. Vaccine. 1999; 18(9-10):825-31. DOI: 10.1016/s0264-410x(99)00321-7. View

14.

Jawed M, Khalid A, Rubin M, Shafiq R, Cemalovic N . Acute Immune Thrombocytopenia (ITP) Following COVID-19 Vaccination in a Patient With Previously Stable ITP. Open Forum Infect Dis. 2021; 8(7):ofab343. PMC: 8294682. DOI: 10.1093/ofid/ofab343. View

15.

Su J, Ng C, Lewis P, Cano M . Adverse events after vaccination among HIV-positive persons, 1990-2016. PLoS One. 2018; 13(6):e0199229. PMC: 6007919. DOI: 10.1371/journal.pone.0199229. View

16.

Ramasamy M, Minassian A, Ewer K, Flaxman A, Folegatti P, Owens D . Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial. Lancet. 2020; 396(10267):1979-1993. PMC: 7674972. DOI: 10.1016/S0140-6736(20)32466-1. View

17.

OBRIEN W, Grovit-Ferbas K, Namazi A, Wang H, Park J, Yeramian C . Human immunodeficiency virus-type 1 replication can be increased in peripheral blood of seropositive patients after influenza vaccination. Blood. 1995; 86(3):1082-9. View

18.

Polack F, Thomas S, Kitchin N, Absalon J, Gurtman A, Lockhart S . Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020; 383(27):2603-2615. PMC: 7745181. DOI: 10.1056/NEJMoa2034577. View